Skip to content

Examination of the effect of silybum marianum on thyroid and antioxidant capacity in patients with bipolar disorders under the treatment of lithium

Examination of the effect of silybum marianum on thyroid and antioxidant capacity in patients with bipolar disorders under the treatment of lithium

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190811044513N2
Enrollment
40
Registered
2020-03-02
Start date
2019-09-22
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with bipolar disorder. Bipolar disorder

Interventions

Intervention 1: Intervention group: The intervention group received 16 mg daily silymarin in addition to standard treatments effective in the depression phase of bipolar disorder. Intervention 2: Cont

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age group 18 to 70 years Patients with diagnosis of bipolar depression disorder by a psychiatrist based on DSM-5 Patients who receiving lithium

Exclusion criteria

Exclusion criteria: Patients with mixed depressive phase with simultaneous manic or hypomanic Pregnant patients Lactating patients

Design outcomes

Primary

MeasureTime frame
Thyroid markers. Timepoint: Before the intervention and 16 weeks after the intervention. Method of measurement: Using the ELISA method.;Serum antioxidant capacity. Timepoint: Before the intervention and 16 weeks after the intervention. Method of measurement: Using the Colorimetric Kit.

Secondary

MeasureTime frame
The mean of liver parameters. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: Using a special kit.;Blood lithium level. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: By the fluorometric method.;Depression Phase Bipolar Disease. Timepoint: Before intervention and 16 weeks after the intervention. Method of measurement: Patient symptoms and physician diagnosis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Ataei

Hamedan University of Medical Sciences

s.ataei@umsha.ac.ir+98 81 3838 1591

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026